-
摘要:
目的 探讨上皮性卵巢癌组织中ATF5(activating transcription faclor 5, ATF5)基因的表达及其临床意义。 方法 采用免疫组织化学染色法和逆转录酶聚合酶链反应(riverse transcription polymerase chain reaction, RT-PCR)方法从蛋白和mRNA水平检测60例上皮性卵巢癌组织、15例良性卵巢肿瘤和9例正常卵巢组织标本中ATF5的表达差异。 结果 上皮性卵巢癌组织中ATF5阳性表达率显著高于正常卵巢及卵巢良性肿瘤组织(P < 0.05), 且ATF5蛋白和mRNA表达强度与上皮性卵巢癌手术病理分期和组织分化程度有关。Ⅲ~Ⅳ期的阳性表达率及表达强度明显高于Ⅰ~Ⅱ期(P < 0.05);低分化组高于中分化及高分化组(P < 0.05), 但中分化及高分化组之间ATF5表达无显著性差异(P > 0.05)。 结论 ATF5在上皮性卵巢癌组织中呈高表达, 其表达强度与临床分期和组织分化程度密切相关, 为卵巢癌的治疗提供新的靶点。 -
关键词:
- 上皮性卵巢癌 /
- 转录激活因子5 /
- 逆转录酶聚合酶链反应 /
- 免疫组化
Abstract:Objective This work aims to investigate the expression and significance of activating transcription factor 5(ATF5) in epithelial ovarian carcinoma. Methods Reverse transcription polymerase chain reaction was used to determine ATF5 mRNA expression. The immunohistochemical staining method was employed to assay the expression of ATF5 protein in the specimens of 60 cases with epithelial ovarian carcinoma, 15 cases of benign ovarian tumor, and 9 cases of normal ovarian tissue. Results ATF5 expression was significantly higher in epithelial ovarian carcinoma than in benign ovarian tumor and normal controls(P < 0.05).The over-expression of ATF5 was related to the differentiation and clinical stage.The positive rates of ATF5 were notably higher in stagesⅢ-Ⅳcarcinoma than in stagesⅠ-Ⅱ(P < 0.05).The positive rates of ATF5 were also higher in the poor differentiation group than in the good and moderate differentiation group.However, no significant differences were found between the groups with cancers of good and moderate differentiations(P > 0.05). Conclusion ATF5 is over-expressed in epithelial ovarian carcinoma.The level of ATF5 expression is related to differentiation and clinical staging.The findings may serve as a foundation for further studies on the correlation between ATF5 and oncogenesis of ovarian cancer, and on the role of ATF5 in biological behaviors of ovarian carcinoma. -
图 1 ATF5蛋白在卵巢癌组织中的表达(×200, 小图×400)
A: 阳性对照组中ATF5蛋白的表达; B: 阴性对照; C~F: ATF5蛋白分别在良性卵巢肿瘤组织、早期卵巢癌组织、晚期卵巢癌组织及正常卵巢组中的表达
Figure 1. Immunohistochemical staining of ATF5 in ovarian cancer (×200, the top right corner×400)
A：The expression of ATF5 in positive control．ATF5 expression was primarily localized in the cytoplasm of tumor cells；B：The expression of ATF5 in negative control；C：The expression of ATF5 in benign ovarian tumor；D：The expression of ATF5 in early stage of ovarian cancer；E：The expression of ATF5 in advanced stage of ovarian cancer；F： The expression of ATF5 in normal ovarian tissue
图 2 RT-PCR检测ATF5 mRNA在卵巢癌中的表达
a: ATF5 mRN A在正常卵巢组织中的表达; b: ATF5 mRNA在良性卵巢肿瘤组织中的表达; c-f: ATF5 mRNA分别在Ⅰ-Ⅳ期上皮性卵巢癌组织中的表达。A-F: 对应a-f各组的内参β-actin mRNA的表达
Figure 2. The expression of ATF5 mRNA in ovarian cancer detected by RT-PCR
表 1 不同卵巢组织中ATF5表达差异 （x±s）
Table 1. Expression of ATF5 in ovarian cancer, benign ovarian tumor and normal ovarian tissue (x±s)
表 2 ATF5与卵巢癌临床分期的关系 （x±s）
Table 2. The relationship between the clinical stage and the expression of ATF5 in ovarian cancer (x±s)
表 3 ATF5与卵巢癌组织分化程度的关系 （x±s）
Table 3. The relationship between the pathological grade and the expression of ATF5 in ovarian cancer (x±s)
-
[1] Hanahan D, Weinberg RA. The hallmarks of cancer[J]. Cell, 2000, 100(1): 57-70. doi: 10.1016/S0092-8674(00)81683-9 [2] Luo J, Solimini NL, Ellcdge SJ. Principles of cancer therapy: oncogene and nononcogene addiction[J]. Cell, 2009, 136(5): 823-837. doi: 10.1016/j.cell.2009.02.024 [3] Hai T, Hartman MG. The molecular biology and nomenclature of the activating transcription factor/cAMP responsive element binding family of transcription factors: activating transcription factor proteins homeostasis[J]. Gene, 2001, 273(1): 1-11. doi: 10.1016/S0378-1119(01)00551-0 [4] Persengiev SP, Green MR. The role of ATF/CREB family members in cell growth, survival and apoptosis[J]. Apoptosis, 2003, 8(3): 225-228. doi: 10.1023/A:1023633704132 [5] Liu W, Sun M, Jiang J, et al. Cyclin D3 interacts with human activating transcription faetor5 and potentiates its transcription activity[J]. Biochem Biophys Res Commun, 2004, 321(4): 954-960. doi: 10.1016/j.bbrc.2004.07.053 [6] Monaco SE, AngelastroJM, Szabolcs M, et al. The transcription facto rATF5 is widely expressed in carcinomas, And interference with its function selectively kills neoplastic, but not nontransformed, breast cell lines[J]. Int J Cancer, 2007, 120(9): 1883-1890. doi: 10.1002/ijc.22469 [7] Mason JL, Angelastro JM, Ignatova TN, et al. ATF5 regulates the proliferation and differentiation of oligodendrocytes[J]. Mol Cell Neurosci, 2005, 29(3): 372-380. doi: 10.1016/j.mcn.2005.03.004 [8] Angelastro JM, Canoll PD, Kuo J, et al. Selective destruction of glioblastoma cells by interference with the activity or expression of ATF5[J]. Oncogene, 2006, 25(6): 907-916. doi: 10.1038/sj.onc.1209116 [9] Dluzen D, Li G, Tacclosky D, et al. Bcl-2 is a downstream target of ATF5 that mediates ATF5' pro-survival function in a cell type-dependent manner[J]. Bio Chem, 2011, 286(9): 7705-7713. doi: 10.1074/jbc.M110.207639 [10] Sheng Z, Evans SK, Green MR. An activating transcription factor 5-mediated survival pathway as a target for cancer therapy[J]? Oncotarget, 2010, 1(6): 457-460. doi: 10.18632/oncotarget.180 -
下载:
点击查看大图
计量
- 文章访问数: 44
- HTML全文浏览量: 25
- PDF下载量: 0
- 被引次数: 0
